Form 4: Apellis General Counsel Receives Significant RSU Grant

Apellis Pharmaceuticals' General Counsel, David O. Watson, was granted 55,986 Restricted Stock Units vesting over four years.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc., acquired 55,986 shares of common stock.
• This acquisition represents a Restricted Stock Unit (RSU) award granted on January 28, 2026.
• The RSUs will vest 25% annually over four years from the grant date, contingent on continued service.
• Following this transaction, Watson directly beneficially owns 144,517 shares.
• Indirect beneficial ownership includes 10,000 shares held in a custodial account for minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive commitment and a standard, well-structured compensation practice that aligns management with long-term shareholder interests.

Positives

• The grant of 55,986 Restricted Stock Units to a key executive aligns management's interests with long-term shareholder value.
• A four-year annual vesting schedule promotes executive retention and sustained performance.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and compliant transaction.

Risks

• The vesting of the Restricted Stock Units is subject to continued service, meaning the executive must remain employed to receive the full benefit of the award.

Future Outlook

The RSU award vests 25% annually over four years from the grant date, contingent on continued service, indicating a long-term incentive structure for the General Counsel.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align executive incentives with long-term company performance and shareholder value creation, common practice among peers like Biogen or Vertex Pharmaceuticals.

Comparison to Industry Standards

• The grant of RSUs with a multi-year vesting schedule is a common practice in the pharmaceutical industry, comparable to compensation structures at companies such as Pfizer or Merck, which use similar long-term incentive plans to retain key talent.
• The size of the grant for a General Counsel role is within typical ranges for a company of Apellis's market capitalization, reflecting competitive executive compensation practices.

Related Party Transactions

• Indirect beneficial ownership is reported through a custodial account for minor children.
• Indirect beneficial ownership is reported through The David O. Watson Irrevocable Trust of 2023.

Stakeholder Impact

• Shareholders: The RSU grant aligns the General Counsel's interests with long-term shareholder value through equity ownership and performance-based vesting.
• Employees: This grant reflects the company's ongoing executive compensation strategy, potentially influencing broader employee incentive programs.

Next Steps

• The RSUs will vest 25% annually over the next four years, subject to David O. Watson's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice. While it signals executive alignment with the company's long-term success, it does not present new fundamental information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as it maintains the current position based on existing company fundamentals.

Keywords

Apellis Pharmaceuticals, APLS, David O. Watson, Restricted Stock Units, RSU, Insider Trading, Form 4, Executive Compensation, Equity Grant, Corporate Governance